Study of brain and whole blood PK/PD of bortezomib in rat models.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.24.18_SUPPL.12036PMID 27953058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

  2021cites this paper
• Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition

  2020cites this paper
• The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities

  2017cites this paper
• Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

  2015cites this paper
• The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

  2009cites this paper
• Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib

  2007cites this paper